This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

GO-RAISE 5-year long-term extension study

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study 1

GO-RAISE Study
Prescribing Information

The GO-RAISE 5-year long-term extension study assesses golimumab efficacy and safety through 5 years in patients with active ankylosing spondylitis (AS)1.

Read the study from the EULAR Journal

By study design, randomisation of weight; patients in the long-term extension may have switched between 50mg and 100mg SIMPONI doses at the discretion of the study physician.

Refer to SIMPONI prescribing information for full licensed weight based dosing.

References:

  1. Deodhar A et al. Ann Rheum Dis 2015; 74: 757–61

More information about SIMPONI® (golimumab):